Sawai Pharmaceutical has agreed to sell its Upsher-Smith Laboratories business to Taiwan’s Bora Pharmaceuticals in a deal worth up to $210m, bringing to an end a near seven-year sojourn in the US market for the Japanese generics giant.
Announcing the divestment – which remains subject to customary regulatory approvals – Sawai cited multiple factors, including buyer consolidation and competition from Indian rivals, as well as the need to focus on its domestic
Key takeaways:
-
Japan’s Sawai has agreed to sell its US Upsher-Smith business to Taiwan’s Bora in a deal worth up to $210m.
-
Upsher-Smith was acquired for $1.05bn by Sawai in 2017.
-
Factors influencing Sawai’s decision to sell included competitive pressures from US purchaser consolidation and Indian rivals, as well as the need to focus on Japan